Immunoglobulin A Nephropathy Clinical Trials

49 clinical trials for Immunoglobulin A Nephropathy across international registries, including 21 currently recruiting participants. Compare status, phase, eligibility criteria and locations.

• A Study to Assess the Effects of Zigakibart on IgA Nephropathy. — RECRUITING · PHASE2
• Study to Assess the Efficacy, Pharmacokinetics, Safety and Tolerability of Atrasentan in Pediatric Patients With Primary IgAN — RECRUITING · PHASE3
• A Study to Learn About the Effects of Felzartamab Infusions on Adults With Immunoglobulin A Nephropathy (IgAN) — RECRUITING · PHASE3
• Study of Ravulizumab in Pediatric Participants With Primary IgAN — RECRUITING · PHASE3
• Study to Evaluate the Impact of Iptacopan on Top of SOC on Biopsy Changes in Kidneys of Adult Patients With IgAN — RECRUITING · PHASE2
• A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Ravulizumab in Adult Participants with Immunoglobulin A Nephropathy (IgAN) — RECRUITING · PHASE3
• Chinese Adults With Kidney Disease — RECRUITING · PHASE2
• A Study of the Safety and Activity of Sparsentan for the Treatment of Patients With Immunoglobulin A Nephropathy — RECRUITING · PHASE2
• A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of Povetacicept in Adults with Immunoglobulin A Nephropathy (RAINIER). — RECRUITING · PHASE3
• Study of Sparsentan Treatment in Pediatrics With Proteinuric Glomerular Diseases — RECRUITING · PHASE2
• Trial of Sibeprenlimab in the Treatment of Immunoglobulin A Nephropathy (IgAN) — RECRUITING · PHASE2
• A Study of MIL116 in Healthy Participants and Patients With IgA Nephropathy. — RECRUITING · PHASE1
• A Study of Cizutamig in Patients With Immunoglobulin A Nephropathy — RECRUITING · PHASE1
• A Mobile App-Based Study to Evaluate Disease Burden and Treatment Patterns in Immunoglobulin A Nephropathy (IgAN) in the US — RECRUITING
• Multicentre Clinical Study to Evaluate the Effect of Personalized Therapy on Patients With Immunoglobulin A Nephropathy. — RECRUITING · PHASE4
• A PHASE 2B, MULTICENTER, OPEN-LABEL, SINGLE-ARM TRIAL TO EVALUATE THE IMPACT OF SIBEPRENLIMAB ON KIDNEY HISTOPATHOLOGY THROUGH REPEAT KIDNEY BIOPSIES IN ADOLESCENTS AND ADULTS WITH IMMUNOGLOBULIN A NEPHROPATHY — RECRUITING · PHASE2
• A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF POVETACICEPT IN ADULTS WITH IMMUNOGLOBULIN A NEPHROPATHY (RAINIER) — RECRUITING · PHASE3
• A PHASE 3, DOUBLE-BLIND, RANDOMIZED, ADAPTIVE DESIGN STUDY TO EVALUATE THE EFFICACY AND SAFETY OF RAVULIZUMAB IN ADULT PARTICIPANTS WITH IMMUNOGLOBULIN A NEPHROPATHY (IGAN) — RECRUITING · PHASE3
• A PHASE 2/3, MULTICENTER, OPEN LABEL TRIAL TO EVALUATE THE LONG TERM SAFETY, TOLERABILITY, AND EFFICACY OF SIBEPRENLIMAB ADMINISTERED SUBCUTANEOUSLY IN SUBJECTS WITH IMMUNOGLOBULIN A NEPHROPATHY — RECRUITING · PHASE2
• A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTIPLE DOSE STUDY TO EVALUATE THE EFFICACY AND SAFETY OF VIS649 IN PARTICIPANTS WITH IMMUNOGLOBULIN A (IGA) NEPHROPATHY. — RECRUITING
• A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 3 STUDY OF THE SAFETY AND EFFICACY OF OMS721 IN PATIENTS WITH IMMUNOGLOBULIN A (IGA) NEPHROPATHY (ARTEMIS-IGAN) — RECRUITING · PHASE3
• A Phase 3, Randomized, Double-blind, Placebo-controlled Study of Atrasentan in Patients with IgA Nephropathy at Risk of Progressive Loss of Renal Function (The ALIGN Study) — TERMINATED · PHASE3
• Randomized, Double-blind, Placebo-controlled, Crossover Study of Atrasentan in Subjects With IgA Nephropathy — COMPLETED · PHASE2
• Trial of Sibeprenlimab in the Treatment of A Nephropathy (IgAN) — ACTIVE_NOT_RECRUITING · PHASE3
• Study of Ravulizumab in Immunoglobulin A Nephropathy (IgAN) — ACTIVE_NOT_RECRUITING · PHASE3
• Atrasentan in Patients With IgA Nephropathy — ACTIVE_NOT_RECRUITING · PHASE3
• Atrasentan in Patients With Proteinuric Glomerular Diseases — ACTIVE_NOT_RECRUITING · PHASE2
• Evaluation of Efficacy of Povetacicept in Adults With Immunoglobulin A Nephropathy (IgAN) — ACTIVE_NOT_RECRUITING · PHASE3
• First in Human Study to Assess Safety of VIS649 in Healthy Subjects — COMPLETED · PHASE1
• Safety and Efficacy Study of VIS649 for IgA Nephropathy — COMPLETED · PHASE2
• A Study of the Effect and Safety of Sparsentan in the Treatment of Patients With IgA Nephropathy — ACTIVE_NOT_RECRUITING · PHASE3
• A Randomized, Multicenter, Double-blind, Parallel-group, Active-control Study of the Efficacy and Safety of Sparsentan for the Treatment of Immunoglobulin A Nephropathy (PROTECT) — TERMINATED · PHASE3
• A Study of Zigakibart in Adults With IgA Nephropathy — ACTIVE_NOT_RECRUITING · PHASE3
• Efficacy and Safety Study of HS-10542 for IgA Nephropathy — NOT_YET_RECRUITING · PHASE2
• A Phase 3, Open-Label, Single-Arm, Multicenter Study to Evaluate the Pharmacokinetics, Pharmacodynamics, Efficacy, and Safety of Ravulizumab in Pediatric Participants (2 to < 18 years of age) with Primary Immunoglobulin A Nephropathy (IgAN) — TERMINATED · PHASE3
• Study of Ravulizumab in Proliferative Lupus Nephritis (LN) or Immunoglobulin A Nephropathy (IgAN) — TERMINATED · PHASE2
• A Study to Investigate Safety and Effect of Sparsentan in Combination With SGLT2 Inhibition in Participants With IgAN — COMPLETED · PHASE2
• Study of ALXN2050 in Proliferative Lupus Nephritis (LN) or Immunoglobulin A Nephropathy (IgAN) — TERMINATED · PHASE2
• An Open-label Study of Povetacicept in Autoantibody-Associated Glomerular Diseases — ACTIVE_NOT_RECRUITING · PHASE1
• Open-Label Study to Evaluate Safety and Efficacy of CCX168 in Subjects With IGA Nephropathy on Stable RAAS Blockade — COMPLETED · PHASE2
• A Study of the Effect and Safety of HS-10390 in the Treatment of Patients with Primary IgA Nephropathy — NOT_YET_RECRUITING · PHASE2
• Study to Evaluate the Safety, Tolerability of BCX9930 in Participants With Either Complement 3 Glomerulopathy (C3G), Immunoglobulin A Nephropathy (IgAN), or Primary Membranous Nephropathy (PMN) — TERMINATED · PHASE2
• Humanistic Burden of (FSGS) Focal Segmental Glomerulosclerosis and IgAN (Immunoglobulin A Nephropathy) — COMPLETED
• A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLEBLIND, PLACEBO-CONTROLLED TRIAL TO EVALUATE THE EFFICACY AND SAFETY OF SIBEPRENLIMAB ADMINISTERED SUBCUTANEOUSLY IN SUBJECTS WITH IMMUNOGLOBULIN A NEPHROPATHY — COMPLETED · PHASE3
• Efficacy and Safety of SM101 in the Treatment of IgA Nephropathy — WITHDRAWN · PHASE2
• The Genital Tract Microflora in Women With Systemic Lupus Erythematosus (SLE) and Immunoglobulin A (IgA) Nephropathy. — OTHER
• A PHASE 2, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF CEMDISIRAN IN ADULT PATIENTS WITH IGA NEPHROPATHY — COMPLETED · PHASE2
• Development of a Metabolic Assessment Tool for Chronic Kidney Disease — COMPLETED · NA
• A PHASE 2 STUDY TO ASSESS THE EFFICACY AND SAFETY OF INTRAVENOUS INFUSION WITH HUMAN SOLUBLE RECOMBINANT FC-GAMMA RECEPTOR IIB (SM101/ BAX 1810) IN SUBJECTS WITH IMMUNOGLOBULIN A NEPHROPATHY (IGAN) — NOT_YET_RECRUITING · PHASE2

Refine this search